Clinical Trials in Los Angeles

Showing 941-960 of 14,465 trials

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT02123758

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.57 participantsStarted Jul 2014

Los Angeles, California, United States • San Francisco, California, United States • Houston, Texas, United States +4 more locations

RECRUITINGEARLY Phase 1< 1 mile

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

NCT04857502

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Prostate CarcinomaRecurrent Prostate Carcinoma

Jonsson Comprehensive Cancer Center30 participantsStarted Apr 2021

Los Angeles, California, United States

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Find Trials by Condition in Los Angeles

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers